Page 1442 - Williams Hematology ( PDFDrive )

1416 Part X: Malignant Myeloid Diseases Chapter 88: Acute Myelogenous Leukemia 1417

104. Patel JP, Gonen M, Figueroa MF, et al: Prognostic relevance of integrated genetic pro- 133. Levis M: FLT3/ITD AML and the law of unintended consequences. Blood 117:6987,
filing in acute myeloid leukemia. N Engl J Med 266:1079, 2012. 2011.
105. Grossmann V, Schnittger S, Kohlmann A, et al: A novel hierarchical prognostic model 134. Yoshimoto G, Miyamoto T, Jabbarzadeh-Tabrizi S, et al: FLT3-ITD up-regulates
of AML solely based on molecular mutations. Blood 120:2963, 2012. MCL-1 to promote survival of stem cell sin acute myeloid leukemia via FLT3-IT-
106. Abdel-Wahab O, Levine RL: Mutations in epigenetic modifiers in the pathogenesis D-specific STAT5 activation. Blood 114:5034, 2009.
and therapy of acute myeloid leukemia. Blood 121:3563, 2013. 135. Brunet S, Labopin M, Esteve J, et al: Impact of FLT3 internal tandem duplication on
107. Grimwade D, Hills RK, Moorman AV, et al: Refinement of cytogenetic classification the outcome of related and unrelated hematopoietic transplantation for adult myeloid
in acute myeloid leukemia: Determination of prognostic significance or rare recurring leukemia in the first remission: A retrospective analysis. J Clin Oncol 30:735, 2012.
chromosomal abnormalities amongst 5,875 younger adult patients treated in the UK 136. Yamamoto Y, Kiyoi H, Nakano Y, et al: Activating mutation of D835 within the activa-
Medical Research Council trials. Blood 116: 354, 2010. tion loop of FLT3 in human hematologic malignancies. Blood 97:2434, 2001.
108. Mauritzson N, Albin M, Rylander L, et al: Pooled analysis of clinical and cytogenetic 137. Mizuno S, Chijiwa T, Okamura T, et al: Expression of DNA methyltransferases
features in treatment-related and de novo adult acute myeloid leukemia and myelo- DNMT1, D1, and 3B in normal hematopoiesis and in acute and chronic myelogenous
dysplastic syndromes based on consecutive series of 761 patients analyzed 1976–1993 leukemia. Blood 97:1172, 2001.
and on 5098 unselected cases reported in the literature 1974–2001. Leukemia 16:2366, 138. Im AP, Sehgal AR, Carroll MP et al: DNMT3A and IDH mutations in acute myeloid
2002. leukemia and other myeloid malignancies: Associations with prognosis and potential
109. Grimwade D, Enver T: Acute promyelocytic leukemia: Where does it stem from? Leu- treatment strategies. Leukemia 28:1774, 2014.
kemia 18:375, 2004. 139. Thol P, Damm F, Ludeking A, et al: Incidence and prognostic influence of DNMT3A
110. Zeisig BB, Kwok C, Zelent A, et al: Recruitment of RXR by homotetrameric RARalpha mutations in acute myeloid leukemia. J Clin Oncol 29:2889, 2011.
fusion proteins is essential for Transformation. Cancer Cell 12:36, 2007. 140. Ley TJ, Ding L, Walther MJ, et al: DNMT3A mutations in acute myeloid leukemia N
111. Cox MC, Panetta P, Venditti A, et al: Comparison between conventional banding Engl J Med 363:2424, 2010.
analysis and FISH screening with an AML-specific set of probes in 260 patients. 141. Marcucci G, Metzeler KH, Schwind S, et al: Age-related prognostic impact of different
Hematol J 24:263, 2003. types of DNMT3A mutations in adults with primary cytogenetically normal acute
112. Paschka P, Marcucci G, l Ruppert AS, et al: Adverse prognostic significance of KIT myeloid leukemia. J Clin Oncol 80:742, 2012.
mutations in adult acute myeloid leukemia with inv(16 and t(8;21): A Cancer and 142. Shivarov V, Gueroguieva R, Stoimenov A, et al: DNMT3A mutation is a poor prog-
Leukemia Group B Study. J Clin Oncol 24:3904, 2006. nosis biomarker in AML: Results of a meta-analysis of 4500 AML patients. Leuk Res
113. Schwind S, Edward CG, Nicolet D, et al: Inv (16)/t(16;16) acute myeloid leukemia 37:1445, 2013.
with non-type A (CBFB-MYH11) fusions associate with distinct clinical and genetic 143. Gaidzik VI, Schlenk RF, Paschka P, et al: Clinical impact of DNMT3A mutations in
features and lack KIT mutations. Blood 212:385, 2013. younger adult patients with acute myeloid leukemia: Results of the AML study group
114. Paschka P, Du J, Schlenk FR, et al: Secondary genetic lesions in acute myeloid leu- (AMLSG). Blood 121:4769, 2013.
kemia with Inv(16) or t(16;16): A study of the German-Austrian AML study group 144. Kihara R, Nagata Y, Kiyoi H, et al: Comprehensive analysis of genetic alterations and
(AMLSG), Blood 121:170, 2013. their prognosis impacts in adult acute myeloid leukemia patients. Leukemia 28:1586,
115. Li Y, Gao L, Luo X, et al: Epigenetic silencing of microRNA-193a contributes to leu- 2014.
kemogenesis in t(8;21) acute myeloid leukemia by activating the PTEN/PI3K signal 145. Ito Y: Oncogenic potential of the RUNX gene family: “Overview.” Oncogene 23:4198,
pathway. Blood 121:499, 2013. 2004.
116. Nakagawa M, Shimabe M, Watanabe-Okochi N, et al: AML1/RUNX1 functions as a 146. Schnittger S, Dicker F, Kern W, et al: RUNX1 mutations are frequent in de novo AML
cytoplasmic attenuator of NF-κB signaling in the repression of myeloid tumors. Blood with noncomplex karyotype and confer an unfavorable prognosis. Blood 117:2348,
118:6626, 2011. 2011.
117. Lughart S, Groschel S, Beverloo HB, et al: Clinical, molecular, and prognostic signif- 147. Gaidzik VI, Bullinger L, Schlenk RF, et al: RUNX1 mutations in acute myeloid leuke-
icance of WHO type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and various other 3q abnor- mia: Results from a comprehensive genetic and clinical analysis from the AML study
malities in acute myeloid leukemia. J Clin Oncol 28:3890, 2010. group. J Clin Oncol 29:1364, 2011.
118. Weisser M, Haferlach C, Haferlach T, et al: Advanced age and high initial WBC influ- 148. Mendler JH, Maharry K, Radmacher MD, et al: RUNX1 mutations are associated
ence the outcome of inv(3)(q21q26)/t(3;3)(q21;q26) positive AML. Leuk Lymphoma with poor outcome in younger and older patients with cytogenetically normal acute
48:2145, 2007. myeloid leukemia and with distinct gene and microRNA expression signatures. J Clin
119. Kayser S, Zucknick M, Dohner K, et al: Monosomal karyotype in adult acute myeloid Oncol 30:3109, 2012.
leukemia: Prognostic impact and outcome after different treatment strategies. Blood 149. Skokowa J, Stenemann D, Katsman-Kuipers JE, et al: Cooperativity of RUNX1 and
119:551, 2012. CSF3R mutations in severe congenital neutropenia: A unique pathway in myeloid
120. Rucker FG, Schlenk RF, Bulolinger L, et al: TP53 alterations in acute myeloid leukemia leukemogenesis. Blood 123:2229, 2014.
with complex karyotype correlate with specific copy number alterations, monosomal 150. Solary E, Bernard OA, Terfferi A, et al: The Ten-Eleven Translocation (TET2) gene in
karyotype, and dismal outcome. Blood 119:214, 2012. hematopoiesis and hematopoietic diseases. Leukemia 38:485, 2014.
121. Welch JS, Ley TJ, Link DC, et al: The origin and evolution of mutations in acute mye- 151. Tian X, Yu Y, Yin J, et al: TET2 gene mutation is unfavorable prognostic factor in
loid leukemia. Cell 150:264, 2012. cytogenetically normal acute myeloid leukemia patient with NPM1+ and FLT3-ITD-
122. Mardi ER, Ding L, Dooling DJ, et al: Recurring mutations found by sequencing an mutations. Int J Hematol 100:96, 2014.
acute myeloid leukemia genome. N Engl J Med 361:1058, 2009. 152. Aslanyan MG, Kroeze LI, Langemeijer SM, et al: Clinical and biological impact of
123. The Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes TET2 mutations and expression in younger adult AML patients treated within the
of adult de novo acute myeloid leukemia. N Engl J Med 268:2059, 2013. EORTC/GIMEMA AML-12 clinical trial. Ann Hematol 92:1401, 2014.
124. Port M, Bottcher M, Thol F, et al: Prognostic significance of FLT3 internal tandem 153. Metzeler KH, Maharry K, Radmacher MD, et al: TET2 mutations improve the new
duplication, nucleophosmin1, and CEBPA gene mutations for acute myeloid leukemia European LeukemiaNet risk classification of acute myeloid leukemia: A Cancer and
patients with normal karyotype and younger than 60 years: A systematic review and Leukemia Group B study. J Clin Oncol 29:1373, 2011.
meta-analysis. Ann Hematol 93:1279, 2014. 154. Green CL, Koo KK, Hills FR, et al: Prognostic significance of CEBPA mutations in a
125. Hirsch P, Qassa G, Marzac C, et al: Acute myeloid leukemia in patients older than 75: large cohort of younger adult patients with acute myeloid leukemia: Impact of double
Prognostic impact of FLT3-ITD and NPM1 mutations. Leuk Lymphoma 16:1, 2014. CEBPA mutations and the interaction with FLT3 and NPM1 mutations. J Clin Oncol
126. Falni B, Mecucci C, Tiacci E, et al: GIMEMA acute leukemia working party. Cytoplas- 28:2739, 2010.
mic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl 155. Taskesen E, Bullinger L, Corbacioglu A, et al: Prognostic impact, concurrent genetic
J Med 352:254, 2005. mutations, and gene expression features of AML with CEBPA mutations in a cohort
127. Schlenk RE, Dohner K, Krauter J, et al: Mutations and treatment outcome in cytoge- of 1183 cytogenetically normal AML patients: Further evidence of CEBPA double
netically normal acute myeloid leukemia. N Engl J Med 358, 1909, 2008. mutant AML as a distinctive disease entity. Blood 1107:2469, 2011.
128. Becker H, Marcucci G, Maharry K, et al: Favorable prognostic impact of NPM1 muta- 156. Fasan A, Haferlach C, Alpermann T, et al: The role of different genetic subtypes of
tions in older pateints with cytogenetically normal de novo acute myeloid leukemia CEBPA mutated AML. Leukemia 28:791, 2013.
and associated gene-and microRNA-expression signatures: A Cancer and Leukemia 157. Grossman V, Haferlach C, Nadarajah N, et al: CEBPA double-mutated acute myeloid
Group B Study. J Clin Oncol 28:596, 2009. leukaemia harbours concomitant molecular mutations in 76.8% of cases with TET2
129. Greiner J, Ono Y, Hofmann S, et al: Mutated regions of nucleophosmin 1 elicit both and GATGA2 alterations impacting prognosis. Br J Haematol 161:642, 2013.
CD4+ and CD8+ T cell responses in patients with acute myeloid leukemia. Blood 120: 158. Paschka P, Schlenk RF, Gaidzik VI, et al: IDH1 and IDH2 mutations are frequent
1282, 2012. genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytoge-
130. Renneville A, Roumier C, Biggio V, et al: Cooperating gene mutations in acute mye- netically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal
loid leukemia: A review of the literature. Leukemia 22:915, 2008. tandem duplication. J Clin Oncol 28:3636, 2010.
131. Small D: Targeting FLT3 for the treatment of leukemia. Semin Hematol 45(3 Suppl 2): 159. Guan L, Gao L, Wang L, et al: The frequency and clinical significance of IDH1 mua-
S17, 2008. tions in Chinese acute myeloid leukemia patients. PLoS One 8:e83334, 2013.
132. Janke H, Pastore F, Schumacher D, et al: Activating FLT3 mutants show distinct 160. Boissel N, Nibourel O, Renneville A, et al: Prognostic impact of isocitrate dehydroge-
gain-of-function phenotypes in vitro and a characteristic signaling pathway profile nase enzyme isoforms 1 and 2 mutations in acute myeloid leukemia: A study by the
associated with prognosis in acute myeloid leukemia. PLoS One 9:e89560, 2014. acute leukemia French association group. J Clin Oncol 28:3717, 2010.

Kaushansky_chapter 88_p1373-1436.indd 1417 9/21/15 11:02 AM